Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
Ticiana Leal, MD
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Neal Ready, MD, PhD
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
Maria Fleseriu, MD, FACE
Beverly MK Biller, MD, FACP
Mark Gurnell, MD
From Data to Decision: Patient Selection and Real-World Application
Christophe Le Tourneau, MD, PhD
Marc Oliva, MD, PhD
The Evidence Base: Key Trials and Emerging Data
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Sara A. Hurvitz, MD, FACP
Tiffany Traina, MD
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Multiple dates available
The Power of Timing: Therapies That Change Outcomes
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Javier Cortes, MD, PhD
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations
Linda Stein Gold, MD
Lakshi Aldredge, MSN, ANP-BC
Najat M. Watch, PA
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
What’s Next for TROP2-Directed ADCs in TNBC?
Redefining First-Line Therapy of Metastatic TNBC: Integrating TROP2-Directed ADCs Into Modern Treatment Strategy
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Chairperson’s Perspective: Incorporating Novel Treatment Options for Schizophrenia Into Clinical Practice - Overcoming Clinical Inertia
Jose Rubio, MD
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
ADT Intensification: The Evidence You Can’t Afford to Miss
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.